ClinicalTrials.gg
CompletedNCT05800418Updated Apr 5, 2023

Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers

A Phase 1 interventional study of Ramucirumab Injection and Ramucirumab Injection [Cyramza] in Gastric Cancer, Non-small Cell Lung Cancer and Colo-rectal Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-05.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 4 months after the study started (first participant enrolled Nov 2019, registered Mar 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing ramucirumab in Stomach Neoplasms — 3 open to participants now, 4 under way, none of them phase 3. Ramucirumab · Stomach Neoplasms.

Enrollment
9th of 20
88 · median 59
Started
2019
with 2 others
Phase 1
2 of 20
1 open now
Registered
17th of 20
by date
Lead sponsor
1 of 20
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 20 studies testing ramucirumab in Stomach Neoplasms, this one is the 9th largest by enrollment, is one of 3 that started in 2019, is one of 2 in phase 1, and was the 17th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

3 of the 20 studies testing ramucirumab in Stomach Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ramucirumab

Ramucirumab: first FDA approval 2014 (CYRAMZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing ramucirumab in Stomach Neoplasms, or all of them as a file.
02

Study summary

Ramucirumab is a biosimilar drug of CYRAMZA® produced by Chiatai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., LTD. It is a vascular endothelial growth factor receptor 2 (VEGFR-2) antagonist. This single-center, randomized, double-blind, single-dose, parallel phase I study of Ramucirumab injection versus Cyramza ® in healthy male volunteers was designed to evaluate the similarities in pharmacokinetics, tolerance, safety and immunogenicity of Ramucirumab and CYRAMZA®.

03

Conditions studied

  • Gastric Cancer
  • Non-small Cell Lung Cancer
  • Colo-rectal Cancer
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign form before the study and fully understand the study content, process and possible adverse reactions;
  • Be able to complete the study according to the requirements of the test plan;
  • Male subjects aged 18-65 years (included);
  • The subject should weigh at least 50kg. (BMI) = weight (kg)/ height2(m2), BMI in the range of 19 to 26 (included);
  • Health status: no mental abnormality, no medical history of abnormal cardiovascular system, nervous system, respiratory system, digestive system, urinary system, endocrine system and metabolism;
  • Normal or abnormal vital signs, physical examination, laboratory examination, and imaging examination with no clinical significance;
  • Have no pregnancy plan and voluntarily take effective measures from 2 weeks before the study drug administration to at least 6 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  • Have a history of neuropsychiatric system, respiratory system, cardiovascular system, digestive system, hemolymph system, liver and kidney insufficiency, endocrine system, skeletal and musculoskeletal system disease or other diseases, and the investigators judge that this history may affect drug metabolism or safety;
  • Known allergic to Ramucirumab or its ; Known history of allergic diseases or allergic constitution;
  • History of hypertension or abnormal blood pressure at screening/baseline measurement (systolic blood pressure (SBP) > 140 mmHg, and/or diastolic blood pressure (DBP) >90 mmHg, confirmed by one repeat measurement on the same day);
  • A history of albuminuria (urine routine examination, albuminuria 2+ and above) or albuminuria as assessed by the investigator;
  • Had received treatment of Ramucirumab or VEGFR2 receptor antagonist, or other antibody or protein drugs that target VEGFR2 receptor;
  • Had received any live viral vaccine within 2 months prior to study drug infusion, or required vaccination between the screening period and the end of the study, had used any monoclonal antibody or biologic drug within 12 months prior to study drug administration, or planned to receive any monoclonal antibody or biologic drug within 12 months after study drug administration;
  • had unhealed wound ulcers or fractures, or had undergone major surgery within 3 months prior to study drug infusion or expected to undergo major surgery during the study period or within 2 months after study completion;
  • had taken any prescription drugs, over-the-counter drugs, any vitamin products, or herbs within 14 days prior to use of the study drug;
  • Patients with abnormal examinations and clinical significance during the screening period;
  • Blood donation or significant blood loss within 3 months prior to use of the study drug (>450 mL);
  • Have taken the study drug or participated in any clinical trial of the drug within 3 months prior to the use of the study drug;
  • Smokers who smoked more than 5 cigarettes a day in the 3 months before the test;
  • Test positive for alcohol or have a history of alcohol abuse (14 units of alcohol per week: 1 unit =360 mL of beer or 45 mL of 40% spirits or 150 mL of wine);
  • Test positive for drugs or have a history of drug abuse in the past five years or have used drugs in the three months prior to the test;
  • Hepatitis (including and C), AIDS, syphilis positive screening;
  • Patients with difficulty in venous blood collection or who cannot tolerate venipuncture;
  • Unable or unable to comply with ward management regulations, poor compliance during the study, or unable to follow protocol requirements to complete the study;
  • Subjects unable to complete the experiment due to personal reasons;
  • Conditions considered unsuitable for inclusion by other researchers.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Ramucirumab injection

    8mg/kg, Single intravenous infusion

    Drug: Ramucirumab Injection

  • Active comparator
    Cyramza

    8mg/kg, Single intravenous infusion

    Drug: Ramucirumab Injection [Cyramza]

Interventions

  • Ramucirumab injection biosimilar products manufactured by Chia Tai Tianqing Pharmaceutical,

  • Ramucirumab Injection is a humanized monoclonal antibody based on the human immunoglobulin G1(IgG1) skeleton sequence, developed by Eli Lilly Co., the bran name is Cyramza. Ramucirumab is a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist that specifically binds to VEGF receptor 2 and blocks VEGFR ligand, VEGF-A, VEGF-C, and VEGF-D binding to the receptor. As a result, Ramucirumab inhibits ligand-stimulated VEGF receptor 2 activation, thereby inhibiting ligand-induced proliferation, and human endothelial cell migration. Ramucirumab inhibits angiogenesis, thereby blocking the tumor's blood vessel supply.

06

What researchers measure

Primary outcomes

  1. Area under drug concentration - time curve (AUC0-t)

    Area under the curve from zero to the lowest detectable blood drug concentration.

    Time frame: Within 60 minutes before administration to 1680 hours after administration.

Secondary outcomes

  1. Area under drug concentration - time curve (AUC0-∞)

    The area under the curve extrapolating from zero to infinity.

    Time frame: Within 60 minutes before administration to 1680 hours after administration.

  2. Peak concentration (Cmax)

    Peak maximum plasma drug concentration

    Time frame: Within 60 minutes before administration to 1680 hours after administration.

  3. Peak concentration time (Tmax)

    Time to reach maximum plasma concentration after dosing

    Time frame: Within 60 minutes before administration to 1680 hours after administration.

  4. Clearance rate (CL)

    Percentage of the organ-scavenging drugs that eliminated by the body

    Time frame: Within 60 minutes before administration to 1680 hours after administration.

  5. Half-life (T1/2)

    The time it takes for serum drug concentrations to drop by half

    Time frame: Within 60 minutes before administration to 1680 hours after administration.

  6. Apparent volume of distribution (Vd)

    Apparent volume of distribution after administration

    Time frame: Within 60 minutes before administration to 1680 hours after administration.

07

Study locations

1 site
  • Affiliated Hospital of Changchun University of Traditional Chinese Medicine
    Changchun, Jilin 130021, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Feb 2020, 3 months.

Of 168 industry-sponsored phase 1 interventional studies under Stomach Neoplasms, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 65. This study's 3 months is below that.

Counting every sponsor, half of 243 studies reached it within 51 months; a quarter within 33 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2023
First posted
Apr 5, 2023
StartActual
Nov 4, 2019
Primary completionActual
Feb 18, 2020
CompletionActual
Feb 18, 2020
Last update
Apr 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05800418
Responsible party
Sponsor
First posted
Apr 5, 2023
Start date
Nov 4, 2019
Primary completion
Feb 18, 2020
Completion
Feb 18, 2020
Last update
Apr 5, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion